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350a Tuesday, February 10, 2015binding and provided a dynamical basis for the efficacy of partial agonists or
full agonists, as well as the modulation of activation by positive allosteric mod-
ulators (PAMs). Finally, our work provides a general model for the activation
process of mGluRs.
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Biased agonism, that is the ligand-dependent selectivity for specific signaling
pathways in a G protein coupled receptor (GPCR), is an emerging, promising
strategy for the development of safer drugs. In the case of the kappa opioid re-
ceptor (KOPr), its preferential activation of G-protein versus b-arrestin has
been proposed to provide a more direct route to discovering non-addictive
opioid therapeutics with reduced side effects. In fact, the KOPr-mediated
dysphoria that usually accompanies the beneficial analgesic effect of KOPr
agonists has recently been attributed to the activation of the p38 mitogen-
activated protein kinase pathway, which is believed to follow arrestin recruit-
ment to the activated KOPr. This observation suggests that KOPr agonists
that selectively activate the G protein, but do not recruit arrestin, may be
more effective analgesics since they would not exhibit the adverse effects trig-
gered by the arrestin pathway.
Based on the above, understanding the structural and chemical determinants of
biased agonism at the KOPr is highly desirable as it can guide the discovery/
design of improved therapeutics. Here, we employ flexible docking of a set
of recently characterized functionally selective KOPr ligands to establish a pre-
dictive model for G protein-biased agonism at this receptor based on character-
istics of modes of interaction between the ligand and the KOPr. We apply the
resulting classifier to a large set of established KOPr agonists to assess their
ability to preferentially promote G protein coupling, arrestin recruitment, or
both.
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G protein-coupled receptors (GPCRs) are the integral membrane proteins that
detect extracellular ligands and mediate signal transduction. Binding of ligands
promotes transitions from inactive to active receptor conformations, which are
recognized by intracellular effectors. Chemically distinct ligands may trigger
different signaling responses by altering dynamics of the receptor. We devel-
oped a single-molecule fluorescence system to observe conformational switch-
ing of the b2-adrenergic receptor in real-time within a native-like membrane
environment. The receptor was covalently labeled with a photostable and
environmentally-responsive Cy3 fluorophore at the cytoplasmic end of either
transmembrane (TM) helix VI or helix VII. Individual receptor molecules
were incorporated in phospholipid nanodiscs, tethered to a microscope cover
slip and visualized over time by total internal reflection fluorescence micro-
scopy. We observed spontaneous transitions of TM helices VI and VII between
inactive and active conformations, even in the absence of any ligands. Studies
of ligands that span a comprehensive range of pharmacological efficacies
showed that full agonists shorten the time spent in the inactive conformations
and prolong the time in the active conformations, leading to an increased pop-
ulation of active species, while an inverse agonist prolonged the time spent in
inactive conformations. These observations provide new insights into the
mechanism of GPCR activation and the molecular basis for the variable phar-
macological efficacies of different drug molecules.
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G-protein-coupled receptor (GPCR) crystal structures reveal exquisite details
of interactions between amino acids and bound ligands. However, little isknown about the pathways by which ligands enter their binding sites. Binding
pathways are essential determinants of association and dissociation rates and
thus underlie kinetic selectivity, a phenomenon in which a ligand primarily
affects a particular receptor despite having similar binding affinity for several
closely related receptors. Protease-activated receptor 1 (PAR1) is a GPCR
whose endogenous agonist is a tethered, water-soluble peptide generated by
thrombin cleavage. By contrast, the PAR1-specific antagonist vorapaxar is a
lipophilic small molecule that binds in a pocket almost entirely occluded
from extracellular solvent.
Based on temperature-accelerated molecular dynamics simulations, we hypoth-
esize that vorapaxar enters the PAR1 binding pocket from the lipid bilayer be-
tween transmembrane helices 6 and 7 (TM6 and TM7). To test this hypothesis,
we take a chemical biology approach and synthesize vorapaxar derivatives with
alkyl chains extending along the predicted binding pathway. In cell signaling
assays, we find that the on-rate for vorapaxar derivatives with increased bulk
between TM6 and TM7 is no slower than that of vorapaxar. These data indicate
that vorapaxar likely enters the binding pocket from the lipid bilayer, through
the cleft between TM6 and TM7. While other groups have reported experi-
mental evidence that retinal binds to rhodopsin through a channel from the lipid
bilayer, our study provides the first such data for a ligand binding to a peptide
GPCR. Membrane drug entry mechanisms, such as the pathway we describe for
vorapaxar binding to PAR1, may be important for understanding kinetic selec-
tivity of lipophilic GPCR ligands and may inform selective drug design.
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TIRF microscopy allows us to visualize individual fluorophores in living cells.
We have developed automated algorithms to detect and track thousands of in-
dividual molecules and have studied GPCRs (G-protein coupled receptors)
tagged with fluorescent ligands or fluorescent proteins in live cultured cells
and freshly dissected tissue slices.
We have found that M1 and M2 muscarinic receptors diffuse freely at the
plasma membrane with their mobility dependent upon both cell-type and tem-
perature. The mobility of M2 receptors tagged with the fluorescent antagonist
(Cy3B-telenzepine) matches the mobility of M2-GFP molecules imaged under
the same conditions. Fluorophore tracking allowed direct observation of tran-
sient homo-dimerisation of M1 and M2 receptors which we confirmed using
two-color imaging. At a membrane receptor density of 2 mm2, 30% of recep-
tors were dimeric and the dimer lifetime was ~1 s1.
We have found that only ~10% of isolated primary cardiomyocytes and cells in
the mice heart slices expressed M2 receptors on the detectable level. The recep-
tors undergo unrestricted diffusion and therefore were evenly distributed across
the cell membrane. The M2 density in freshly isolated embryonic cardiomyo-
cytes was ~1 mm2, increasing at birth to ~3 mm2 and decreasing back to
~1 mm2 after birth. Whilst some M2 receptors formed reversible dimers the
majority were monomeric. The receptor mobility was approximately 4-times
faster in freshly dissected heart slices (0.6 mm2 s1) than in cultured primary
cardiomyocytes. Knowing receptor mobility and density we used Monte Carlo
simulations to estimate an encounter rate of 5-10 collisions per second. This
may explain the observed electrophysiological latency between the application
of acetylcholine and GIRK channel opening.
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The CD14 co-receptor is specialized for recognition of bacterial lipopolysac-
charide (LPS). On the surface of macrophages and other immune cells, it trans-
fers LPS and its bioactive component lipid A to the MD-2 protein in complex
with Toll-Like Receptor 4 (TLR4), and is hence crucial in activating the innate
immune system via the TLR4 signalling pathway. In the case of severe infec-
tions, lipid A can cause sepsis through over-activation of the immune
response, leading to multiple organ failure and death, and has become a major
target for anti-septic drugs. Unfortunately, the mechanism by which lipid A
is transferred to CD14, and the detailed mode(s) of associated binding, are
